Cancer play Seragon raises $30 million in A round

Seragon Pharmaceuticals Inc. (San Diego, Calif.) raised $30 million in a series A round from venBio; Topspin Fund; Aisling Capital; OrbiMed Advisors and The Column Group. Seragon's ARN-810 is in Phase I testing for estrogen receptor-positive breast cancer. The compound is an oral selective estrogen receptor degrader (SERD). ...